Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lerapolturev - Istari Oncology

Next Previous
Search
Drug Profile

Lerapolturev - Istari Oncology

Alternative Names: Polio Virus Sabin-Rhinovirus Poliovirus; PVS-RIPO; Re-engineered poliovirus; Recombinant-polio-virus-vaccine-Istari-Oncology; Sabin type 1 polio vaccine - Istari Oncology

Latest Information Update: 10 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Duke University Medical Center
  • Developer Duke University Medical Center; Istari Oncology; National Cancer Institute (USA)
  • Class Antineoplastics; Attenuated vaccines; Cancer vaccines; Gene therapies; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma; Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma; Malignant melanoma
  • Phase I/II Solid tumours
  • No development reported Breast cancer; Prostate cancer

Most Recent Events

  • 24 Oct 2024 Istari Oncology terminates the phase I/II trial in Solid tumours (Late-stage disease, Monotherapy) in USA due to business decision (Intratumoural) (NCT04690699)
  • 24 Oct 2024 Istari Oncology terminates the phase I/II trial in Solid tumours (Late-stage disease, Combination therapy) in USA due to business decision (Intratumoural) (NCT04690699)
  • 04 Sep 2024 Istari Oncology in collaboration with Duke University terminates a phase I trial in Malignant melanoma (Late-stage disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (Intratumoural) due to business decision prior to enrolling Cohort 4(NCT03712358)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top